Evidence map›Paper›PMID 40905116›Full record

ReviewArteriosclerosis, thrombosis, and vascular biology2025

Profibrinolytic Factors and Cancer Progression, Metastasis, and Survival.

Yohei Hisada, Nigel Mackman

Abstract readReview
In one paragraph

Review in Arteriosclerosis, thrombosis, and vascular biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Enhanced Fibrinolysis in Lung Cancer Patients: A Functional Assessment Using Lysis Slope Time and Fibrinolytic Biomarkers.Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Yohei HisadaDivision of Hematology, Department of Medicine, UNC Blood Research Center, University of North Carolina at Chapel Hill.ORCID 0000-0001-9157-0524
Nigel MackmanDivision of Hematology, Department of Medicine, UNC Blood Research Center, University of North Carolina at Chapel Hill.ORCID 0000-0002-9170-7700

Funding

Tissue factor-dependent coagulation in thrombosis and immune responsesR35HL155657 · NHLBI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Nigel Mackman · 2021 to 2026
$5.5M
Mechanisms of coagulopathy and bleeding in acute promyelocytic leukemiaR56HL171301 · NHLBI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI HISADA, YOHEI M · 2024 to 2024
$765k
NHLBI NIH HHS R35 HL155657NHLBI NIH HHS R56 HL171301
6 · The paper itself

Abstract

The primary role of the fibrinolytic system is to degrade fibrin clots. However, the fibrinolytic system is often activated in patients with cancer and may affect cancer progression, metastasis, and patient survival. Clinical studies have shown that elevated plasma levels of uPA (urokinase plasminogen activator) are associated with cancer progression in patients with prostate, bladder, and cervical cancers, whereas high plasma levels of soluble uPAR (uPA receptor) are associated with progression and metastasis in prostate, breast, bladder, and colorectal cancers. Elevated levels of plasmin-α

Indexed as

FibrinolysisNeoplasmsAnimalsDisease ProgressionFibrinolysinHumansNeoplasm MetastasisReceptors, Urokinase Plasminogen ActivatorSignal TransductionTissue Plasminogen ActivatorUrokinase-Type Plasminogen ActivatorFibrinolysinReceptors, Urokinase Plasminogen ActivatorTissue Plasminogen ActivatorUrokinase-Type Plasminogen Activatoranimal modelsbiomarkersfibrinolysisneoplasm ◼ plasminogen ◼ tissue plasminogen activatorurokinase-type plasminogen activator

Identifiers

PMID40905116
PMCPMC12576909

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.